Company Contact: Bruce N. Barron, CEO
(847) 573-8025 ext. 240
Agency Contact: Ira Weingarten/Steve Chizzik
APNS Discusses Diagnosing Alzheimer's Disease on CEOcast Today
Vernon Hills, IL December 10, 2003 - Applied NeuroSolutions, Inc. (OTC BB: APNS) headquartered here, a world leader in the diagnosis of Alzheimer's disease, today announced its senior management is currently featured in an online interview with CEOcast.com.
During the interview, Chairman and CEO Bruce N. Barron and President and COO Dr. John F. DeBernardis presented an update on the company's progress in developing a cerebrospinal fluid (CSF) test to detect Alzheimer's disease at a very early stage with 85%-95% sensitivity and specificity. The CSF test, which distinguishes between Alzheimer's and other related disorders, such as depression, stroke and Parkinson's, is expected to begin pivotal clinical trials during the first quarter of calendar 2004. Management also discussed a second-stage, serum-based screening test that is also in an advanced stage of development.
The interview is available at http://www.ceocast.com
To access it, just click where it says "Register Free" in the upper right corner.
About Applied NeuroSolutions
In partnership with a team of distinguished scientists at Albert Einstein College of Medicine, Applied NeuroSolutions (OTC BB: APNS) is developing an integrated product portfolio for the diagnosis and treatment of Alzheimer's disease (AD). The company recently signed research agreements with Pfizer, Inc. (NYSE: PFE) and Novartis AG (NYSE: NVS) and expects to enter pivotal clinical trials with its lead diagnostic product in Q1 2004.
CEOcast produces original and syndicated streaming broadcast interviews of chief executive officers at public and private news-making companies and distributes its programming to millions of online investors at over 700 financial web sites as well as to more than 20,000 portfolio managers, buy-side analysts and traders at more than 3,300 North American institutions. Content is also disseminated to over 7,000 investment research professionals representing over 425 institutions.
This press release contains forward-looking statements. Applied NeuroSolutions wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the need to raise substantial additional equity capital, and the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, and potential competitive offerings. For further information, please visit the company's new website at www.appliedneurosolutions.com, and review the company's filings with the Securities and Exchange Commission.